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Hereditary Breast Cancer in Northern Ireland
A G McKinley, S E H Russell, R A J Spence, W Odling-Smee, N C Nevin
SUMMARY
The aim of this investigation was to document hereditary breast cancer in Northern Ireland.
Family history details from over nine hundred women were obtained by postal survey and one
hundred and twenty nine home visits were carried out to collect pedigree information. The
familiesdocumentedvariedinthenumberofaffectedwomenfromthree,whichwastheminimum
criteria for inclusion, to a maximum of nine and many families described other features of
hereditary disease such as bilateral breast cancer, ovarian and gastrointestinal malignancies.
INTRODUCTION
Afamily history ofbreastcancer is recognised as
one of the most important risk factors for the
disease.".2Inthemajorityofwomenbreastcancer
is due to a multifactorial combination of
environmental and genetic factors. However
breast cancer in some women is due to a major
genetic influence. Several epidemiological" 2, 3
studies have suggested that an autosomal
dominant gene may be present in approximately
three per thousand individuals, and that this is
responsible for a substantial proportion of the
familial clustering of breast cancer in the
population. It is now established that in some
familiesthehighincidenceofbreastcancerisdue
to amutation in agene, known as BRCA1, which
is located on the long arm ofchromosome 17.4 5
Hereditary breast cancer has a number of
distinguishing features6 which include early age
ofonset ofbreastcancer, an autosomal dominant
pattern of inheritance, an association with other
malignancies, an excess ofbilateral disease and a
better prognosis. It was decided to undertake a
study to document hereditary breast cancer
families within the community.
METHODS
Suitable families were identified by selecting
pre-menopausalwomenwhohaddevelopedbreast
cancer. In addition, specialist breast clinics, a
charitycancerscreeningorganisation andgeneral
practitioners wereinvolvedinidentifyingfamilies
containing at least three women who had
developed breast cancer.
All women in Northern Ireland who developed
pre-menopausal breast cancer in the five years
between January 1986 and January 1991 were
identified through pathology records. Patients
with a diagnosis of invasive breast carcinoma,
either ductal or lobular, were selected. Most
histopathology records are computerised but
manual documentation was necessary in two of
the hospitals in Northern Ireland.
Details ofwomen with a family history ofbreast
cancer were obtained from three sources.
1. 'At risk' patients attending specialist breast
clinics in either the Royal Victoria or Belfast
City Hospitals.
2. General Practitioners werecontactedby letter
and referral of suitable families requested.
3. Women attending 'Action Cancer' for breast
cancer screening within the period January
1986-January 1991 wereascertained,although
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the medical records for a longer period were
available.
All women identified were sent a postal
questionnairerequestingdetailsregardingfamily
history ofbreast and other cancers. The returned
questionnaires weremanuallycheckedanddetails
were stored on computer (Amstrad Locofile)
which prevented inclusion ofany family already
identified, and avoided multiple ascertainment.
Those families which fulfilled the criteria of at
least three affected women were contacted and a
home visit was arranged to obtain apedigree and




sources are shown in TableI. There was atotal of
3425 new patients with breast cancer diagnosed
inNorthernIrelandwithin thefiveyearperiod, of
which 727 were aged47 years or less. For 632 of
these patients we were able to establish a name
and address; the remaining 95 women could not
be contacted as hospital records had insufficient
information.
TABLE I
Number ofpre-menopausal women with breast
cancer: source ofreferral, number identified
and number with at least three affected women.
Source of Number Number
Patients identified with three
affected
relatives
Pre-menopausal women 632 47
Clinical referral 87 35
General practitioner referral 13 4
Action Cancer records 170 78
Total 902 164
From other sources two hundred and seventy
women were identified and in total nine hundred
and two women were sent a questionnaire. Six
hundred and forty-seven questionnaires were
returned, (58%) and one hundred and sixty-four
families fulfilled the criteria of three or more
affected women.
Onehundredandtwenty-ninewomenwerevisited
at home. Of the remaining thirty-five families,
TABLE II
Number offamilies identified with number of
affected women perfamily *










* Previously published data -
Br J Surg 1995; 82: 1086-1088.
TABLE III





Bilateral breast cancer 38
One ovarian malignancy 18
Two or more ovarian malignancies 4
One gastrointestinal malignancy 10
Two or more gastrointestinal
malignancies 17
Male breast cancer 3
twenty-one werereluctanttotake anyfurtherpart
in the study, and nine who did not include a
telephone numberin theirreturnedquestionnaire
failed to respond to a posted request to arrange a
home visit. In five instances although the family
agreed to a home visit, various family
circumstances prevented this during the study
period. Inf fr families the death of a family
memberfrom breast cancer meant thatthe family
were too distressed to discuss details of the
pedigree. One family moved to another part of
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the United Kingdom before a visit could be
arranged. Pedigree details are shown in Table II.
Many families revealed additional features in
their pedigree suggestive of hereditary disease.
These include bilateral breast cancer, other
malignancies inthefamilyandmalebreastcancer
(Table III).
Families were also classified into three groups
depending on age at onset ofdisease. There were
forty-six families in which all affected women in
thefamilywereaged47 yearsorlessatdiagnosis.
There was a group in which the majority, but not
all, of the breast cancers developed in the pre-
menopausal period. This group, which contained
fifty-four families, was described as Mixed.
Twenty-nine families showed predominantly
post-menopausal onset of breast cancer.
DISCUSSION
Five hundred and nine women with hereditary
breast cancer have been identified in Northern
Ireland using multiple sources of ascertainment.
The sources used are similar to those reported in
other studies although many of these relied on a
single source of ascertainment and a realistic
comparison between methods of family
identification is not possible.
The majority of breast cancers develop in the
post-menopausalperiod;pre-menopausaldisease
normally accounts for approximately 20% ofthe
total.7 This is borne out in our study from
histopathology records in which 727 (21%)
women developed pre-menopausal disease.
Previous studies have shown that 20% ofwomen
who develop pre-menopausal breast cancer will
have another relative with breast cancer.7 8
Analysis of pedigrees in this study allowed
identification of 28% hereditary breast cancer
families. However from the total 632 pre-
menopausal breast cancers it might have been
expected to identify more than the 47 (7.5%)
families (Table I).
Action Cancer provided an important source of
breast cancer-prone women, contributing more
than 50% of the total families identified as
containingthreeormoreaffectedwomen.Women
attending Action Cancer are often self-referrals
for breast cancer screening. This suggests that
the availability of a Breast Cancer Family clinic
will attract concerned families. The number of
referrals from the general practitioners was low
and this possibly reflects the use of a manual
system for medical records in some practices
which would preventrapid, easy identification of
familiescontaining severalmemberswithcancer.
The criteria for inclusion in the study ofthree or
more affected family members has been used in
most other studies. However breast cancer is
common in Northern Ireland (142 per 100,000)9
andthreeaffectedmemberswithin afamilycould
also result from the clustering ofsporadic breast
cancers. There is evidence from local genetic
analysis studies that some families with three
affected members do trace susceptibility to the
gene BRCAl'° These families which contain
only three affected members demonstrate the
difficulties associatedwithgeneticanalysiswhen
the pedigree shows a nuclear family pattern.
It may be that some families containing a smaller
number ofaffected members represent the effect
of environmental influence in combination with
the incomplete penetrance documented for
BRCA1.5 It is also possible that there are several
BRCA1 mutationsinthepopulationwithvariation
in expression depending on the degree of
penetrance of some mutations.
The majority of families (78%) described either
three or four affected women but twenty-four
families contained either five or six affected
women. Despite such ahigh incidence ofdisease
less than 30% of unaffected women from these
families attended either Action Cancer or a
specialist breast clinic. Both the families
containing nine affected women were identified
through the attendance of an unaffected relative
at a specialist breast clinic but even in these
families many unaffected women, despite the
availability of such a facility, do not attend for
surveillance. This may seem surprising but a
study of breast cancer families has shown that a
common reaction to the serious threat of breast
cancer is denial. This type of denial reaction is
associated with a reluctance to attend for
surveillance, and a delay in seeking medical
attention when a breast lump is discovered.8 A
more recentstudy reports thatmany women from
breast cancer prone families underestimate their
risk ofbreast cancer and despite counselling feel
that their risk of breast cancer is only slightly
greater than that of the general population."
The development of bilateral breast cancer is
very suggestive ofhereditary disease6 andastudy
has shown thatawoman withunilateral hereditary
breastcancerhas almosta50%o riskofdeveloping
a second breast cancer if she survives over a
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twenty year period.8 In addition women who
develop breast cancer when aged less than fifty
years have more than five times the risk of
developing a second breast cancer than those
womenwhoexhibitpost-menopausal disease.8 In
ourstudy38families showedevidenceofbilateral
breastcanceralthough this trait was notconfined
tothefamilies withparticularly large numbers of
affected women. However there did seem to be
morebilateral disease in thefamilies in which the
majority of women had developed pre-
menopausaldisease, inthatall ofthe women with
bilateral breast cancer were from families
classified as eitherpre-menopausal or mixed age
at onset of disease.
In 22 families at least one woman had developed
ovarian cancer. Although there is some evidence
that a small number of families with multiple
breast and ovarian cancers are not linked to
BRCA1 most publications suggest that BRCAI
is responsible for disease in the majority ofthese
families.4 5 If appropriate surveillance is
undertaken then clearly women in such families
must be offered regular monitoring for
gynaecological neoplasia. Itisrecommended that
unaffected women from these families have six
monthly pelvic ultra-sound surveillance.6
Twenty-seven families (25%) contained at least
one relative with a gastrointestinal cancer. Large
bowel cancer is common in Northern Ireland




Early onset of disease is perhaps the most
characteristic feature ofhereditary breastcancer2
and there were forty-six families in which all
affected women were aged less than 47 years at
diagnosis. In a study including combined results
from ten different centres throughout the United
StatesandEuropeinvolving214families in which
DNA analysis was used to investigate familial
susceptibility to BRCAI, there was strong
evidence for an association between early onset
breast cancer prone families and BRCAI but
little evidence for families showing post-
menopausal onset of disease.
In this study twenty-nine families showed
predominantly late-onset of breast cancer. A
similar study noted 19 late-onset families.S
However, the majority of reports made no
comment on late-onset disease. This may be due
to family identification methods, as clinical
referral may select early-onset breast cancer
families. A Swedish study in which there was a
numberoflate-onsetfamiliesusedapostal survey
system to ascertain families.'3 It is possible that
infamilieswithlateonsetofbreastcanceranother
gene may be involved, for example a region on
chromosome 614 or indeed on another as yet
unidentified gene.
Those families which were classified as mixed,
in which the majority of women showed pre-
menopausal breastcancerbutoneormorewomen
developed breast cancer post-menopausally may
represent variation in penetrance of hereditary
breastcancergenes, orthepost-menopausal cases
may be due to the developmentofsporadic breast
cancer within a hereditary breast cancer family
which has been documented.
There are many undiscovered families in the
community, as evidenced by a continued
accumulation offamilies through Action Cancer
and clinical referral. If the frequency ofBRCA1
in the general population is 0.003" 2, then it
would be expected that in the population of
Northern Irelandofroughly oneandahalfmillion
there will beapproximately 2250femalecarriers.
If 5%6 of breast cancers are hereditary, then in
Northern Ireland about 30 women could be
expected to develop breast cancer each year as a
result of a major gene.
CONCLUSION
Women with a family history of breast cancer,
whether linked to BRCA1 or to some other gene,
have a high risk of developing the disease." 2,5
Frequently these women are young, and they
have the added risk of bilateral disease.5' 15,16
Little information from controlled clinical trials
is available as to the effectiveness of screening
for breast cancer in young, high-risk women and
it may be very difficult to obtain.'7
There are increasing requests for information,
counselling and surveillance from patients and
general practitioners. The rapid development of
molecular genetic diagnostic techniques and
generalpublic awarenessthroughmediapublicity
demand an organised team approach.
It is suggested that this demand is best served by
a breast cancer family clinic where women with
a family history of breast cancer can obtain
accurateriskcounsellingfromamedical geneticist
with backupfrom amoleculargenetic laboratory.
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In addition appropriate surveillance requires a
specialist breast surgeon, with the availability of
bothcytopathology andradiologybreastimaging
services.
Apart from families who were identified either
through attendance at specialist breast clinics or
'Action Cancer' breast screening we found little
evidence that breast cancer-prone women attend
forgeneticassessmentorscreeninginvestigation.
Whenthepossibility wasdiscussed,usuallywhen
obtaining apedigree, many women expressed an
interest in attending abreast cancer family clinic
butatpresentthistypeofserviceisunavailable in
Northern Ireland. This study shows that families
and women can be identified in the Northern
Ireland community who are at risk ofdeveloping
breast cancer and who may benefit from such a
clinic.
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